CSL Reports Profits Up 63 Percent for FY 2009; Swine Flu Data Expected Next Month
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Melbourne-headquartered CSL reported this week that it posted AU$1.15 billion ($943 million) in net profits for FY2009, up 63 percent year on year. With cash flow from operations of AU$1.03 billion, the company is well positioned for an alternative acquisition target after scuttling its $3.1 billion merger with U.S.-based Talecris
You may also be interested in...
CSL Highlights Gum Disease Vaccine Partnership With Sanofi Pasteur And Acute Heart Disease Compound At R&D Briefing
PERTH, Australia - Melbourne-based CSL Limited focused on two new products about to enter the clinic during its Dec. 10 R&D briefing, including a new vaccine to treat severe gum disease, which it is co-developing with Sanofi Pasteur
CSL Highlights Gum Disease Vaccine Partnership With Sanofi Pasteur And Acute Heart Disease Compound At R&D Briefing
PERTH, Australia - Melbourne-based CSL Limited focused on two new products about to enter the clinic during its Dec. 10 R&D briefing, including a new vaccine to treat severe gum disease, which it is co-developing with Sanofi Pasteur
CSL Highlights Gum Disease Vaccine Partnership With Sanofi Pasteur, Cardio Drug, During R&D Update
Research suggests periodontal disease leads to systemic threats, including cardiovascular disease, oropharyngeal and pancreatic cancers and diabetes, expert says.